​

Funding Round

Series A - LinKinVax

Series A - LinKinVax

Investment Firm

Overview

LinKinVax operates as a clinical-stage biotechnology company.

Announced Date

Jan 09, 2023

Funding Type

Series A

Highlights

Location

Europe

Social

Investor Lead

In-Q-Tel

In-Q-Tel

In-Q-Tel is a debt and early_stage_venture and grant and late_stage_venture and seed firm.

André-Jacques Auberton-Hervé

André-Jacques Auberton-Hervé

No designation

Participant Investors

2

Investor Name
Participant InvestorAndré-Jacques Auberton-Hervé
Participant InvestorIn-Q-Tel

Round Details and Background

LinKinVax raised $7834905 on 2023-01-09 in Series A

LinKinVax operates as a clinical-stage biotechnology company.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 10, 2022
Seed Round - LinKinVax
6-5.0M
Jan 09, 2023
Series A - LinKinVax
2-7.8M

Recent Activity

There is no recent news or activity for this profile.